Project Grant F32DA065349
Award Date 11/30/26
Completion Date 6/14/29
Dollars Obligated $157K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Birmingham, AL 35294, USA
Similar Awards
- The National Institute on Drug Abuse awarded the University of Alabama at Birmingham $409,750 on August 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a secondary data analysis of national Medicaid claims examining variations in clinician responses to Prescription Drug Monitoring Program mandates. The recipient will analyze how emergency department, urgent care, and primary care clinicians adopt opioid prescribing regulations and policies differently,...
- The National Institute on Drug Abuse awarded the University of Alabama at Birmingham $661,299 on August 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research into opioid use disorder mechanisms and potential therapeutic targets. The research, titled "A Novel Cellular and Circuit Target for Opioids," investigates a transcriptionally distinct neuronal population in the nucleus accumbens that expresses high levels of the mu opioid receptor...
- The National Institute on Drug Abuse awarded the University of Alabama at Birmingham $1.788 million on April 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a Type 1 hybrid effectiveness-implementation randomized controlled trial testing a remote intervention to prevent overdose among people who use stimulants and opioids. The award funds the R61 phase of a two-phase study designed to isolate the independent impact of remote education on overdose outcomes...
- The National Institute on Drug Abuse awarded the University of Alabama at Birmingham $1.765 million on April 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate how cannabis use impacts T cell phenotype, HIV seeding and persistence in the central nervous system, and neuropathogenesis in people living with HIV. The project, titled "The Impact of Substance Use on the Role of T Cells in HIV CNS Reservoir Seeding, Persistence, and Neuropathogenesis,"...
- The National Institute on Drug Abuse awarded the University of Pittsburgh $198,164 on September 25, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research examining delta opioid receptor regulation of parvalbumin interneuron transmission and oxycodone-related behavior. The project investigates how delta opioid receptor signaling in parvalbumin-expressing GABAergic interneurons within the prefrontal cortex contributes to opioid use disorder symptoms,...
- The National Institute on Drug Abuse awarded the University of Maryland, Baltimore $659,796 on June 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a five-year, double-blind, placebo-controlled human laboratory trial examining the risks and therapeutic benefits of combined opioid and gabapentin use among individuals with chronic pain. The study evaluates the effects of gabapentin and hydromorphone, alone and in combination, on risk for non-medical use,...
- The National Institute on Drug Abuse awarded the University of Utah $162,200 on October 10, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to characterize pain embodiment and its relationship to opioid misuse risk in chronic pain using neuroimaging. The award funds a five-year research project through September 30, 2030, performed in Salt Lake City, Utah. The research will employ resting-state functional magnetic resonance imaging to study pain embodiment—the tendency...
- The National Institute on Drug Abuse awarded Auburn University $173,128 on November 29, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support training and experimental research on the neurobiological mechanisms underlying cannabis use disorder. The project, titled "Experimental Manipulation of the Emotional Salience of Cannabis Use-Related Information," will provide training in transcranial magnetic stimulation (TMS) methodology, magnetic resonance imaging...
- The National Institute on Drug Abuse awarded the Trustees of Boston University $164,190 on January 9, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct basic research on the role of the GAZ protein in opioid-induced behavioral responses. The research investigates how the G alpha Z (GAZ) protein mediates mu-opioid receptor signaling in specific brain regions to distinguish analgesic pathways from addiction-related pathways. The work uses conditional knockout...
- The National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health under the Department of Health and Human Services, awarded the University of Maryland, Baltimore $4.929 million on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and validate a multi-omic, psychosocial, and environmental model of individual differences in pain and placebo responses. The project investigates chronic pain conditions, particularly...